These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

816 related items for PubMed ID: 15603272

  • 21. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].
    Burdan F, Korobowicz A.
    Pol Merkur Lekarski; 2003 Apr; 14(82):352-5. PubMed ID: 12868201
    [Abstract] [Full Text] [Related]

  • 22. [Analgesic effects of cyclooxygenase 2 inhibitors].
    Jayr C.
    Bull Cancer; 2004 May; 91 Spec No():S125-31. PubMed ID: 15239341
    [Abstract] [Full Text] [Related]

  • 23. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
    Tindall E.
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
    [Abstract] [Full Text] [Related]

  • 24. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H, Bombardier C, Davis P, Russell AS, Third Canadian Consensus Conference Group.
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
    Lee MC, Lee S, Suh DC, Kim J, Kong SX, Korea Arthritis Study Group.
    Curr Med Res Opin; 2003 Jan; 19(7):597-602. PubMed ID: 14606981
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Non-steroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors].
    Miehle W.
    Wien Med Wochenschr; 1999 Jan; 149(19-20):541-5. PubMed ID: 10637962
    [Abstract] [Full Text] [Related]

  • 30. [New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
    Oliw E, Wollheim FA.
    Lakartidningen; 2000 Jun 14; 97(24):2942-4. PubMed ID: 10900877
    [No Abstract] [Full Text] [Related]

  • 31. The coxibs, selective inhibitors of cyclooxygenase-2.
    FitzGerald GA, Patrono C.
    N Engl J Med; 2001 Aug 09; 345(6):433-42. PubMed ID: 11496855
    [No Abstract] [Full Text] [Related]

  • 32. COX-2 inhibitors: new drugs for the management of pain and inflammation.
    Hutchins V, Hutchins B.
    Dent Today; 2001 Feb 09; 20(2):56-61. PubMed ID: 12524847
    [No Abstract] [Full Text] [Related]

  • 33. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.
    Gastroenterology; 2003 Feb 09; 124(2):288-92. PubMed ID: 12557133
    [Abstract] [Full Text] [Related]

  • 34. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D.
    Thromb Haemost; 2006 Oct 09; 96(4):407-12. PubMed ID: 17003915
    [Abstract] [Full Text] [Related]

  • 35. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors.
    Stephens J, Laskin B, Pashos C, Peña B, Wong J.
    Rheumatology (Oxford); 2003 Nov 09; 42 Suppl 3():iii40-52. PubMed ID: 14585917
    [Abstract] [Full Text] [Related]

  • 36. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ, Wentworth C, Burke TA, Makuch RW.
    Pharmacoepidemiol Drug Saf; 2004 May 09; 13(5):277-87. PubMed ID: 15133778
    [Abstract] [Full Text] [Related]

  • 37. Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs.
    Scheiman JM.
    Am J Manag Care; 2002 Nov 09; 8(17 Suppl):S518-28. PubMed ID: 12458821
    [Abstract] [Full Text] [Related]

  • 38. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 39. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy].
    Burdan F, Korobowicz A.
    Pol Merkur Lekarski; 2003 Apr 24; 14(82):348-51. PubMed ID: 12868200
    [Abstract] [Full Text] [Related]

  • 40. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
    Davies NM, Jamali F.
    J Pharm Pharm Sci; 2004 Oct 29; 7(3):332-6. PubMed ID: 15576013
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.